,75 A decrease in left ventricular ejection fraction of ≥10% to <50% occurred in 3% to 5.5% of patients in the FLAURA (A Phase III, Double-Blind, Randomized Study of Osimertinib versus Gefitinib or Erlotinib in Previously Untreated Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer) and AURA3 (A Phase III, Open Label, Randomized Study of osimertinib versus Platinum-Based Doublet Chemotherapy in Patients with EGFR T790M Positive Advanced NSCLC) trials, with older age and hypertension being risk factors.76 Here, EGFR is linked to non-small cell lung carcinoma.